Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01486316 · ClinicalTrials.gov registry record · NA
Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01486316 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 24 participants.
The verdict
NCT01486316, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the feasibility and impact of a diagnostic tool that may help clinicians identify when patients are at higher risk of visiting the hospital for a heart failure event. The study will use a non-experimental device that is inserted just under the skin of the chest, which continuously monitors the heart rhythm in combination with an experimental web-based heart failure risk status. Patients with atrial fibrillation and heart failure will be evaluated to collect data about the potential of this risk status to help improve patient outcome.
Interventions
- DEVICE Reveal XT® Insertable Cardiac Monitor
- OTHER Heart Failure Risk Status Diagnostic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01486316
The ClinicalTrials.gov registry entry for NCT01486316 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Reveal XT® Insertable Cardiac Monitor is the first listed.
NCT01486316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01486316 about?
NCT01486316 is a clinical study titled "Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure". The purpose of this study is to characterize the feasibility and impact of a diagnostic tool that may help clinicians identify when patients are at higher risk of visiting the hospital for a heart failure event. The study will use a non-experimental device that is inserted just under the skin of the...
What is the current status of trial NCT01486316?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2011-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01486316?
The interventions under investigation include: Reveal XT® Insertable Cardiac Monitor (DEVICE), Heart Failure Risk Status Diagnostic (OTHER).
Who is sponsoring clinical trial NCT01486316?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.